LTR Pharma is a Clinical Stage Biopharmaceutical Company
Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.
SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects
LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years
worldwide expected cases by 2025
minute effectiveness
projected global market value 2024
ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.
LTR Pharma Scientific and Clinical Advisor and consultant urological surgeon, Professor Eric Chung was recently interviewed by Cayle Reid at Men’s Health Australia to discuss external factors that can influence performance in the bedroom. Professor Chung commented: “Sex is about emotional and physical satisfaction, and both factors can play a
LTR Pharma has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024. Key highlights from this period include: Pivotal clinical study of SPONTAN® fully recruited and completed dosing of all participants. SPONTAN achieved key manufacturing validation and first commercial
LTR Pharma has today announced that all patients recruited for its pivotal bioequivalence clinical study of SPONTAN® nasal spray have now received their second and final dose, completing the recruitment and dosing stage of the clinical study. The Study is evaluating the relative bioavailability of SPONTAN, a novel and proprietary
9/204 Alice Street, Brisbane QLD 4000
Phone: 1800 519 711